The current therapy options available for the treatment of aggressive breast cancers consists fundamentally of hormone therapies, human epidermal growth factor receptor 2 (HER2)+ receptor targets, and chemotherapies, used sometimes in combination with immunotherapies. The gene discussed is ERBB2; the disease is breast carcinoma.